Tonapofylline

Research use only, not for human use.

A potent, selective and orally bioavailable adenosine A1 (A1A) receptor antagonist with Ki of 7 nM.

A potent, selective and orally bioavailable adenosine A1 (A1A) receptor antagonist with Ki of 7 nM; displays 915-foldselectivity over A2A receptor, 12-fold over A2B receptor; increases sodium excretion and cause natriuresis without causing kaliuresis or reducing renal function.Heart Failure Phase 2 Discontinued.

——

Animal Model:Female viral antigen-free Sprague-Dawley rats Dosage:1 mg/kg Administration:Oral administration; twice a day, days 0-6 Result:Produced sustained reductions in post-NSC 119875 serum creatinine and blood urea nitrogen levels, improved body weight recovery and significant attenuation of NSC 119875-induced (5.5 mg/kg) kidney pathology scores.

BG 9928 | BG9928

Apoptosis

Adenosine Receptor

Adenosine Receptor

——

——

340021-17-2

416.522

C22H32N4O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (240.09 mM)

O=C(O)CCC1(CC2)CCC2(C(N3)=NC(N(CCC)C(N4CCC)=O)=C3C4=O)CC1

1,3-dipropyl-8-[1-(4-propionate)-bicyclo-[2,2,2]octyl]xanthine

(-20℃)

With Ice Pack

≥ 2 years